Foamix Pharmaceuticals Ltd. (FOMX) Cut to Sell at Zacks Investment Research
Zacks Investment Research lowered shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) from a hold rating to a sell rating in a research report report published on Tuesday morning.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
Several other research analysts have also weighed in on the stock. Credit Suisse Group restated a buy rating and set a $9.00 target price on shares of Foamix Pharmaceuticals in a research report on Wednesday, July 19th. HC Wainwright initiated coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, August 24th. They set a buy rating and a $12.00 target price on the stock.
Shares of Foamix Pharmaceuticals (FOMX) opened at 6.45 on Tuesday. Foamix Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $11.27. The firm’s 50-day moving average price is $5.28 and its 200 day moving average price is $4.99. The company’s market cap is $241.40 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.50 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. Equities research analysts anticipate that Foamix Pharmaceuticals will post ($1.53) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in FOMX. Baird Financial Group Inc. acquired a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at approximately $188,000. AXA grew its position in shares of Foamix Pharmaceuticals by 19.3% in the first quarter. AXA now owns 826,437 shares of the specialty pharmaceutical company’s stock valued at $4,091,000 after purchasing an additional 133,602 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at approximately $2,217,000. Marshall Wace North America L.P. acquired a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at approximately $2,217,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at approximately $307,000. Institutional investors and hedge funds own 57.60% of the company’s stock.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.